Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly’s weight loss drug dominance 

Amgen, Viking Therapeutics, Altimmune, AstraZeneca, Boehringer Ingelheim and Zealand Pharma are making encouraging progress on their own treatments.

Previous post Swimming in High-Interest Waters
Next post Fed’s Kashkari doesn’t rule out a rate hike